title: Tetracycline-encapsulated P(3HB) microsphere-coated 45S5 Bioglass(®)-based scaffolds for bone tissue engineering.
abstract: Bioglass(®)-based scaffolds for bone tissue engineering have been developed, which can also serve as carriers for drug delivery. For this, P(3HB) microspheres (PMSs) loaded with tetracycline were fabricated and immobilised on the scaffold surfaces by a modified slurry dipping technique. The sustained drug delivery ability in simulated body fluid was confirmed by using UV-Vis absorption spectroscopy measurements. The MTT assay using mouse fibroblast cells provided evidence that the tetracycline loaded microspheres produced in this study show limited cytotoxicity. The scaffolds developed in this work provide mechanical support, adequate 3D surface roughness, bioactivity and controlled drug delivery function, and are thus interesting candidates for bone tissue engineering applications.
authors.affiliation: Department of Materials, Imperial College London, London, SW7 2BP, UK.
authors.forename: D
authors.initials: D
authors.lastname: Meng
authors.forename: L
authors.initials: L
authors.lastname: Francis
authors.forename: I D
authors.initials: ID
authors.lastname: Thompson
authors.forename: C
authors.initials: C
authors.lastname: Mierke
authors.forename: H
authors.initials: H
authors.lastname: Huebner
authors.forename: A
authors.initials: A
authors.lastname: Amtmann
authors.forename: I
authors.initials: I
authors.lastname: Roy
authors.forename: A R
authors.initials: AR
authors.lastname: Boccaccini
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000737:chemistry; D018786:Bone Substitutes / Q000737:chemistry; D001842:Bone and Bones / Q000737:chemistry; D002516:Ceramics / Q000737:chemistry*; D020099:Coated Materials, Biocompatible; D004337:Drug Carriers; D016503:Drug Delivery Systems; D005347:Fibroblasts / Q000166:cytology; D005898:Glass / Q000737:chemistry*; D008422:Materials Testing; D051379:Mice; D008863:Microspheres; D013752:Tetracycline / Q000008:administration & dosage / Q000737:chemistry*; D013778:Tetrazolium Salts; D013844:Thiazoles; D023822:Tissue Engineering / Q000379:methods*; D054457:Tissue Scaffolds
chemical_list: D000900:Anti-Bacterial Agents; D018786:Bone Substitutes; D020099:Coated Materials, Biocompatible; D004337:Drug Carriers; D013778:Tetrazolium Salts; D013844:Thiazoles; C425330:bioactive glass 45S5; C022616:thiazolyl blue; D013752:Tetracycline
references.citation: Int J Mol Sci. 2011;12(7):4294-314
references.pmid: 21845079
references.citation: J Mater Sci Mater Med. 2009 Oct;20(10):2139-44
references.pmid: 19437104
references.citation: Biomacromolecules. 2006 Aug;7(8):2249-58
references.pmid: 16903667
references.citation: Biomaterials. 2006 Apr;27(11):2414-25
references.pmid: 16336997
references.citation: J Biomed Mater Res A. 2008 Mar 15;84(4):1049-60
references.pmid: 17685403
references.citation: J Biomed Mater Res B Appl Biomater. 2004 Aug 15;70(2):240-9
references.pmid: 15264306
references.citation: Adv Drug Deliv Rev. 2007 May 30;59(4-5):339-59
references.pmid: 17499384
references.citation: Int J Nanomedicine. 2011;6:2521-31
references.pmid: 22072886
references.citation: J Control Release. 2007 Oct 8;122(3):338-44
references.pmid: 17644208
references.citation: Acta Biomater. 2012 Feb;8(2):792-801
references.pmid: 22040685
references.citation: Adv Drug Deliv Rev. 2012 Sep;64(12):1292-309
references.pmid: 22342771
references.citation: J Biomed Mater Res. 2001 May;55(2):151-7
references.pmid: 11255166
references.citation: Biomaterials. 2001 May;22(9):897-901
references.pmid: 11311008
references.citation: Acta Biomater. 2010 Jul;6(7):2773-86
references.pmid: 20056174
references.citation: Biomaterials. 2011 Oct;32(29):7068-78
references.pmid: 21704367
references.citation: Biomaterials. 2004 Jan;25(2):327-33
references.pmid: 14585720
references.citation: J Control Release. 2007 Sep 26;122(2):173-80
references.pmid: 17655962
references.citation: Acta Biomater. 2011 Mar;7(3):1307-18
references.pmid: 20971219
references.citation: Pharm Dev Technol. 1999;4(4):581-91
references.pmid: 10578513
references.citation: J Biotechnol. 2007 Nov 1;132(3):251-8
references.pmid: 17532079
references.citation: Biomaterials. 2011 Apr;32(11):2757-74
references.pmid: 21292319
references.citation: J Pharm Sci. 2009 Apr;98(4):1317-75
references.pmid: 18729202
references.citation: J Tissue Eng Regen Med. 2009 Feb;3(2):139-48
references.pmid: 19170250
references.citation: J Biomed Mater Res. 1999 Oct;47(1):18-27
references.pmid: 10400876
references.citation: J R Soc Interface. 2010 Feb 6;7(43):209-27
references.pmid: 19864265
references.citation: AAPS PharmSciTech. 2009;10(4):1158-71
references.pmid: 19842042
references.citation: Expert Opin Drug Deliv. 2011 Dec;8(12):1555-69
references.pmid: 22017669
references.citation: J Microencapsul. 1992 Jan-Mar;9(1):73-87
references.pmid: 1613646
references.citation: Int J Pharm. 2004 Apr 15;274(1-2):261-8
references.pmid: 15072801
references.citation: Tissue Eng Part B Rev. 2010 Apr;16(2):199-207
references.pmid: 19831556